Immunization with HCV synthetic peptides conjugated to the P64k protein elicited strong antibody response in mice

Biotecnologia Aplicada

Volumn 20, Issue 4, 2003, Pages 209-213

  Alvarez Lajonchere, Liz ^a   Martínez, Gillian ^a   Morales, Juan ^a   Aguilar, Julio C ^a   Dueñas Carrera, Santiago ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Antibody response; Carrier protein; HCV; HVR I; P64k

Indexed keywords

EID: 49249102051     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kiyosawa K, Tanaka E, Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. In: Hepatitis C virus and hepatocellular carcinoma. Curr Stud Hematol Blood Transf. Basel: Karger 1998;62:161-80.
2. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993;67:1385-95.
3. Lechmann M,Liang TJ. Vaccine develpment for hepatitis C. Semin Liver Dis 2000;20:211-26.
4. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-512.
5. Zibert A, Kraas W, Meisel H, Jung G, Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 1997;71:4123-7.
6. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995;208:653-61.
7. Lee SW, Cho JH, Lee KJ, Sung YC. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol Cells 1998;8:444-51.
8. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-8.
9. Gonzalez S, Alvarez A, Caballero E, Vina L, Guillen G, Silva R. P64k meningococcal protein as immunological carrier for weak immunogens. Scand J Immunol 2000;52:113-116.
10. Dueñas-Carrera S, Morales J, Acosta-Rivero N, Lorenzo LJ, García C, Ramos T, et al. Variable level expression of hepatitis C virus core protein in a prokaryotic system. Analysis of the humoral response in rabbit. Biotecnologia Aplicada 1999;16:226-31.
11. Guillén G, Alvarez A, Silva R, Morera V, Gonzales S, Musacchio A, et al. Expression in Escherichia coli of the ludA gene: Protein sequence análisis and immunological characterization of the P64k protein from Neisseria meningitidis. Biotechnol. Appl Biochem 1998;27:189-96.
12. Houghten RA, DeGraw ST, Bray MK, Hoffmann SR, Frizzell ND. Simultaneous multiple peptide synthesis: the rapid preparation of large numbers of discrete peptides for biological, immunological, and methodological studies. BioTechniques 1986;4:522-6.
13. N2 deprotection of synthetic peptides with a low concentration of HF in dimethyl sulfide: evidence and application in peptide synthesis. J Am Chem Soc 1983;105:6442-55.
14. Deen C, Claassen E, Gerritse K, Zegers ND, Boersma WJA. A novel carbodiimide coupling method for synthetic peptides: Enhanced antipeptide antibody responses. J Immunol Methods 1990;129:119-125.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
16. Lorenzo LJ, García O, Acosta-Rivero N, Dueñas-Carrera S, Martínez G, Alvarez-Obregón JC, et al. Expresión and immunological evaluation of the Escherichia Coli-derived hepatitis C virus enverlope E1 protein. Biotechnol Appl Biochem 2000;32:137-143.
17. Falcon V, Garcia C, de la Rosa MC, Menendez I, Seoane J, Grillo JM.. Ultrastructural and immunocytochemical evidences of core-particle formation in the methylotrophic Pichia pastoris yeast when expressing HCV structural proteins (core-E1). Tissue Cell 1999;31:117-125.
18. Geerligs HJ, Weijer WJ, Welling GW, Weling WS. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J Immunol Meth 1989;124:95-102.
19. Fattom a, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccine. Vaccine 1999;17:126-133.
20. Beekman NJ, Schaaper WM, Turkstra JA, Meloen RH. Highly immunogenic and fully synthetic peptide-carrier constructs targetting GnRH. Vaccine 1999;17:2043-2050.
21. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes Intervirology 2001;44:98-114.
22. Lorenzo LJ, Dueñas-Carrera S, Falcón V, Acosta-Rivero N, González E, de la Rosa MC, et al. Assembly of truncated HCV core antigen into virus-like particles in E. coli. Biochem Bioph Res Commun 2001;281:962-965.
23. Alvarez-Obregon JC, Dueñas-Carrera S, Valenzuela C, Grillo JM. A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. Vaccine 2001;19:3940-3946.
24. Jackson P, Petrik J, Alexander GJM, Pearson G, Allain J-P. Reactivity of synthetic peptides representing selected regions of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J Med Virol 1997;51:67-79.
25. Wang Y-F, Brotman B, Andrus L, Prince AM. Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis 1996;173:808-821.
26. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587.
27. Puntoriero G, Meola A, Lahm A, Zucchelli S, Ercole BB, Tafi R, et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 1998;17:3521-3533.
28. Goto J, Nishimura S, Esumi M, Makizumi K, Rikihisa T, Nishihara T, et al. Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1. Hepatol Res 2001;19(3):270-83.
29. Kato N, Nakazawa T, Ootsuyama Y, Sugiyama K, Ohkoshi S, Shimotohno K. Virus isolate-specific antibodies against hypervariable region 1 of the hepatitis C virus second envelope protein, gp70. Jpn J Cancer Res 1994;85:987-991.
30. Dueñas-Carrera S, Alvarez-Lajonchere L, Cesar Alvarez-Obregon J, Perez A, Acosta-Rivero N, Vazquez DM, et al. Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with poly-protein-encoding plasmids. Biotechnol Appl Biochem 2002;35:205-212.
31. Fournillier A, Depla E, Karayiannis P, Vidalin O, Maertens G, Trepo C, et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 1999;73:7497-7504.
32. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus - positive blood donors without viremia. Hepatology 1996;24(4):790-5.